Core Viewpoint - Hangzhou Xianweida Biotechnology Co., Ltd. announced that its product, Xianyida® (Enogratide Injection), has received approval from the National Medical Products Administration (NMPA) for blood sugar control in adult patients with type 2 diabetes, marking it as the world's first approved cAMP-biased GLP-1 receptor agonist [1] Company Summary - Xianweida Biotechnology has successfully developed a novel diabetes treatment that has gained regulatory approval, indicating a significant milestone for the company in the biopharmaceutical sector [1] - The approval of Xianyida® positions the company as a pioneer in the market for cAMP-biased GLP-1 receptor agonists, potentially enhancing its competitive edge [1] Industry Summary - The approval of Xianyida® reflects ongoing innovation in diabetes treatment options, particularly in the GLP-1 receptor agonist category, which is crucial for managing type 2 diabetes [1] - This development may influence market dynamics and encourage further research and investment in similar therapeutic areas within the biopharmaceutical industry [1]
先为达生物埃诺格鲁肽注射液获批用于成人2型糖尿病患者血糖控制
Mei Ri Jing Ji Xin Wen·2026-01-30 06:29